TLN1

Summary

TLN1 (talin 1, HGNC:11845) is a protein-coding gene on chromosome 9p13.3, encoding Talin-1 (Q9Y490). High molecular weight cytoskeletal protein concentrated at regions of cell-matrix and cell-cell contacts. It is a selective cancer dependency (DepMap: 56.1% of cell lines).

This gene encodes a cytoskeletal protein that is concentrated in areas of cell-substratum and cell-cell contacts. The encoded protein plays a significant role in the assembly of actin filaments and in spreading and migration of various cell types, including fibroblasts and osteoclasts. It codistributes with integrins in the cell surface membrane in order to assist in the attachment of adherent cells to extracellular matrices and of lymphocytes to other cells. The N-terminus of this protein contains elements for localization to cell-extracellular matrix junctions. The C-terminus contains binding sites for proteins such as beta-1-integrin, actin, and vinculin.

Source: NCBI Gene 7094 — RefSeq curated summary.

At a glance

• Gene–disease (curated): idiopathic spontaneous coronary artery dissection (Moderate, GenCC) — +1 more curated relationship
• GWAS associations: 7
• Clinical variants (ClinVar): 321 total — 1 likely-pathogenic
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 56.1% of screened cell lines
• MANE Select transcript: NM_006289

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11845
Approved symbol	TLN1
Name	talin 1
Location	9p13.3
Locus type	gene with protein product
Status	Approved
Aliases	ILWEQ
Ensembl gene	ENSG00000137076
Ensembl biotype	protein_coding
OMIM	186745
Entrez	7094

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 4 retained_intron, 3 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000314888, ENST00000378192, ENST00000464379, ENST00000465002, ENST00000466916, ENST00000486788, ENST00000489255, ENST00000495712, ENST00000706939, ENST00000912154

RefSeq mRNA: 1 — MANE Select: NM_006289 NM_006289

CCDS: CCDS35009

Canonical transcript exons

ENST00000314888 — 57 exons

Exon	Start	End
ENSE00000928241	35699032	35699156
ENSE00000928242	35699356	35699461
ENSE00000928243	35699974	35700081
ENSE00000928244	35700191	35700376
ENSE00000928249	35704669	35704815
ENSE00000928253	35706196	35706366
ENSE00000928254	35706450	35706551
ENSE00000928255	35706768	35706900
ENSE00000928256	35707072	35707253
ENSE00000928257	35707348	35707488
ENSE00000928258	35707731	35707892
ENSE00000928259	35708341	35708484
ENSE00000928260	35710561	35710683
ENSE00000928261	35710797	35710886
ENSE00000928262	35710989	35711082
ENSE00000928263	35711255	35711394
ENSE00000928264	35711595	35711792
ENSE00000928265	35712005	35712124
ENSE00000928266	35712835	35713043
ENSE00000928267	35713196	35713298
ENSE00000928268	35713953	35714081
ENSE00000928270	35714574	35714687
ENSE00000928271	35714760	35714876
ENSE00000928272	35715059	35715187
ENSE00000928273	35716390	35716556
ENSE00000928274	35717146	35717440
ENSE00000928275	35717619	35717786
ENSE00000928277	35719074	35719282
ENSE00000928278	35719519	35719627
ENSE00000928279	35719740	35719853
ENSE00000928280	35720039	35720219
ENSE00000928281	35720433	35720509
ENSE00000928282	35720812	35720913
ENSE00000928284	35722119	35722223
ENSE00000928285	35722861	35722921
ENSE00000928286	35723952	35724079
ENSE00001429527	35714239	35714373
ENSE00001476780	35732075	35732195
ENSE00001688684	35721648	35721803
ENSE00001900879	35696948	35697916
ENSE00003484692	35724830	35724959
ENSE00003493835	35698808	35698933
ENSE00003495883	35703560	35703676
ENSE00003498304	35703991	35704174
ENSE00003502206	35705551	35705670
ENSE00003536036	35698617	35698679
ENSE00003550241	35725565	35725727
ENSE00003556858	35724192	35724334
ENSE00003571836	35704332	35704498
ENSE00003576729	35705750	35705851
ENSE00003581464	35725224	35725321
ENSE00003583717	35724572	35724724
ENSE00003602577	35705962	35706111
ENSE00003619543	35698044	35698172
ENSE00003674170	35698323	35698505
ENSE00003694240	35703775	35703900
ENSE00003997544	35718812	35718910

Expression profiles

Bgee: expression breadth ubiquitous, 269 present calls, max score 99.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 89.1485 / max 825.2482, expressed in 1828 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100642	56.4481	1821
100646	31.3431	1803
100640	0.8488	503
100641	0.5085	272

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
popliteal artery	UBERON:0002250	99.57	gold quality
tibial artery	UBERON:0007610	99.57	gold quality
ascending aorta	UBERON:0001496	99.53	gold quality
aorta	UBERON:0000947	99.52	gold quality
thoracic aorta	UBERON:0001515	99.52	gold quality
lower esophagus muscularis layer	UBERON:0035833	99.50	gold quality
lower esophagus	UBERON:0013473	99.49	gold quality
right coronary artery	UBERON:0001625	99.47	gold quality
artery	UBERON:0001637	99.46	gold quality
descending thoracic aorta	UBERON:0002345	99.46	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	99.46	gold quality
left coronary artery	UBERON:0001626	99.41	gold quality
muscle layer of sigmoid colon	UBERON:0035805	99.39	gold quality
mucosa of stomach	UBERON:0001199	99.33	gold quality
body of uterus	UBERON:0009853	99.30	gold quality
stromal cell of endometrium	CL:0002255	99.25	gold quality
left uterine tube	UBERON:0001303	99.22	gold quality
coronary artery	UBERON:0001621	99.20	gold quality
right lung	UBERON:0002167	99.07	gold quality
apex of heart	UBERON:0002098	99.06	gold quality
tendon of biceps brachii	UBERON:0008188	99.03	gold quality
peripheral nervous system	UBERON:0000010	99.01	gold quality
nerve	UBERON:0001021	99.01	gold quality
tibial nerve	UBERON:0001323	99.01	gold quality
granulocyte	CL:0000094	98.99	gold quality
colonic epithelium	UBERON:0000397	98.96	gold quality
upper lobe of left lung	UBERON:0008952	98.96	gold quality
monocyte	CL:0000576	98.90	gold quality
endocervix	UBERON:0000458	98.85	gold quality
omental fat pad	UBERON:0010414	98.83	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 10.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	37.71
E-CURD-112	yes	36.49
E-MTAB-9221	yes	24.99
E-CURD-122	yes	24.19
E-HCAD-6	yes	19.91
E-HCAD-10	yes	17.23
E-MTAB-9067	yes	13.13
E-MTAB-9388	yes	10.62
E-HCAD-1	yes	6.25
E-GEOD-124858	no	378.87
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXF2

miRNA regulators (miRDB)

69 targeting TLN1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-8084	99.73	69.57	1760
HSA-MIR-4527	99.66	67.43	714
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-6503-5P	99.62	66.96	597
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-4269	99.55	69.89	1373
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-4498	99.47	67.42	2360

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 56.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• we show that the type I phosphatidylinositol phosphate kinase isoform-gamma 661 (PIPKI gamma 661), an enzyme that makes PtdIns(4,5)P(2), is targeted to focal adhesions by an association with talin (PMID:12422220)
• TLN1 is critical for force-dependent reinforcement of initial integrin-cytoskeleton bonds. (PMID:14581461)
• the integrin-binding site within the talin rod domain is important for beta(3)-cytoskeletal interactions but does not participate in alpha(IIb)beta(3) activation (PMID:15031296)
• The F-actin binding capacity of Talin 1 is regulated by intrasteric occlusion of primary actin-binding determinants within the talin I/LWEQ module. (PMID:15581353)
• two head-tail interfaces cooperate to suppress activation of vinculin by talin (PMID:15728584)
• Talin is essential for the stability and formation of the LFA-1 zone. Disruption of the talin-integrin link leads to loss of zone integrity and a substantial decrease in speed of migration on ICAM-1. (PMID:15983060)
• vinculin binding to talin depends on stability of the helical bundles that make up the talin rod (PMID:16407302)
• These findings suggest that talin F1 may be important in regulation of integrin binding and talin head-rod interaction. (PMID:16546176)
• data provide the first direct evidence that integrin binding site 2 in the talin rod is essential to link integrins to the cytoskeleton (PMID:17430904)
• Results decribe a mechanism in which signals from the T cell receptor produce WAVE2-ARP2/3-mediated de novo actin polymerization, leading to integrin clustering and high-affinity binding through the recruitment of vinculin and talin. (PMID:17591693)
• talin induced an intermediate affinity alphaLbeta2 that adhered constitutively to its ligand intercellular adhesion molecule ICAM-1 but not ICAM-3. (PMID:17591777)
• talin 1 is a versatile VLA-4 affinity regulator implicated in both spontaneous and chemokine-triggered rapid adhesions to VCAM-1. (PMID:17597073)
• Our results suggest that this conserved dimerization motif in the I/LWEQ module plays an essential role in the function of Talin1 as a component of focal adhesions and the other I/LWEQ module proteins in other multicomponent assemblies involved. (PMID:17722883)
• The expression of vinculin constructs with unmasked binding sites in the head and tail regions induces dramatic focal adhesion growth, which is mediated by their direct interaction with talin. (PMID:18056416)
• Upon phosphorylation of Tyr 747 in the beta3 integrin tail, however, Dok1 then binds much more strongly than talin. (PMID:18156175)
• the vinculin-talin-integrin system have a role in the transduction of mechanical force to the extracellular matrix (PMID:19148538)
• GATA-1, G208S MTC are deficient in talin, and what little is present relocates to the undersurface of the plasma membrane following activations where it associates with adhesion plaques. (PMID:19437340)
• F0F1 domain is essential for talin-induced activation of integrin alphaLbeta2 (LFA-1). (PMID:19903453)
• This review discusses the general function of talin 1 and talin 2, as well as vinculin/metavinulin, with emphasis on what is understood about their role in the cardiac myocyte and in whole heart. (PMID:19952892)
• Talin1 profiling in human prostate specimens revealed a significantly higher expression of cytoplasmic talin1 in metastatic tissue compared with primary prostate tumors. (PMID:20160039)
• Zap70 modulates integrin activation by interacting with talin, which contributes to directionality of T-cell migration, severing as a potential target for anti-inflammation therapy. (PMID:20488542)
• Rap1-mediated activation of alpha(M)beta(2) in macrophages shares both common and distinct features from Rap1 activation of alpha(IIb)beta(3) expressed in CHO cells. (PMID:20665668)
• Studies suggest that the perturbed orientation of talin relative to the membrane in the F2 mutant would be expected to in turn perturb talin/integrin interactions. (PMID:20947017)
• Data from talin crystal structure reveal a novel FERM domain with a linear domain arrangement, plus an additional domain F0 packed against F1. (PMID:20947018)
• p130Cas, Src and talin function in both oral carcinoma invasion and resistance to cisplatin. (PMID:21291860)
• We show that sequential cleavage of C-terminal amino acids from the beta(2) cytoplasmic tail of LFA-1, by CatX, enhances binding of the adaptor protein talin to LFA-1 and triggers formation of the latter’s high-affinity form (PMID:21454358)
• Adhesions within the carcinoma matrix create a matrix environment in which exposure to cisplatin induces proliferation through the function of integrin beta, talin and FAK pathways that regulate NF-kB nuclear activity. (PMID:21720550)
• Talin-1 and vinculin negatively affect tyrosine phosphorylation of paxillin, a novel positive regulator of HIV-1 infection, and impose an early block to infection by distinct retroviruses. (PMID:21763488)
• Talin-1 upregulation is associated with disease progression in hepatocellular carcinoma. Thus, it may serve as a prognostic marker. (PMID:21846996)
• We investigated the role of talin-1, kindlin-3, and alpha-actinin-1 in the upregulation of alpha(4)beta(1) integrin affinity and consequent inflammatory leukocyte adhesive events (PMID:21911599)
• Talin1 is required for inside-out activation of integrin beta1 during Bartonella henselae infection. (PMID:22045736)
• Talin1 is required for contact-dependent CD4-positive T cell proliferation in talin1 transgenic mice. Talin1 is not required for contact-independent CD4+ T cell proliferation. (PMID:22075696)
• FAK promotes talin recruitment to nascent adhesions occurring independently of talin binding to beta1 integrins. (PMID:22270917)
• Low Talin1 is associated with hepatocelluar carcinoma. (PMID:22471464)
• Kindlin-2 and talin head do not interact with one another but can bind simultaneously to the integrin beta(3) tail without enhancing or inhibiting the interaction of the other binding partner. (PMID:22648415)
• Data suggest that the signaling elements IL-6, IL-8, OPN, TLN1, and CTGF are involved with NF-kappaB p65 in random positioning machine (RPM)-dependent thyroid carcinoma cell spheroid formation. (PMID:22964303)
• Agonist stimulation, talin-1, and kindlin-3 are crucial for alpha(IIb)beta(3) activation in a human megakaryoblastic cell line, CMK. (PMID:23022222)
• Talin1 has unique expression versus talin 2 in the heart and modifies the hypertrophic response to pressure overload. (PMID:23266827)
• Data indicate that KIF14 and TLN1 loss-of-function significantly enhanced chemosensitivity in four triple-negative breast cancer (TNBC) cell lines. (PMID:23479679)
• miR-9 plays a role as a tumor suppressor in OSC by suppressing TLN1 expression. (PMID:23722670)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tln1	ENSDARG00000100729
mus_musculus	Tln1	ENSMUSG00000028465
rattus_norvegicus	Tln1	ENSRNOG00000016630
drosophila_melanogaster	rhea	FBGN0260442
caenorhabditis_elegans	tln-1	WBGENE00006771

Paralogs (2): TLNRD1 (ENSG00000140406), TLN2 (ENSG00000171914)

Protein

Protein identifiers

Talin-1 — Q9Y490 (reviewed: Q9Y490)

All UniProt accessions (1): Q9Y490

UniProt curated annotations — full annotation on UniProt →

Function. High molecular weight cytoskeletal protein concentrated at regions of cell-matrix and cell-cell contacts. Involved in connections of major cytoskeletal structures to the plasma membrane. With KANK1 co-organize the assembly of cortical microtubule stabilizing complexes (CMSCs) positioned to control microtubule-actin crosstalk at focal adhesions (FAs) rims.

Subunit / interactions. Part of a complex composed of THSD1, PTK2/FAK1, TLN1 and VCL. Interacts with THSD1; this promotes interaction with PTK2/FAK1 and VCL. Binds with high affinity to VCL and with low affinity to integrins. Interacts with APBB1IP; this inhibits VCL binding. Interacts with PTK2/FAK1. Interacts with PIP5K1C and NRAP. Interacts with LAYN. Interacts with SYNM. Interacts with ITGB1; the interaction is prevented by competitive binding of ITGB1BP1. Interacts with SVEP1. Interacts (via R7 domain) with KANK1 or KANK2 (via KN motif); this interaction likely initiates the assembly of cortical microtubule stabilization complexes (CMSCs) at the vicinity of focal adhesions. Interacts with VCL; shows reduced VCL binding compared to isoform 2. Interacts with APBB1IP; shows similar level of binding compared to isoform 2. Interacts with VCL; shows enhanced VCL binding compared to isoform 1. Interacts with APBB1IP; shows similar level of binding compared to isoform 1. (Microbial infection) Interacts with human cytomegalovirus protein UL135.

Subcellular location. Cell projection. Ruffle membrane. Cytoplasm. Cytoskeleton. Cell surface. Cell junction. Focal adhesion.

Tissue specificity. Expressed at low to non-detectable levels in many tissues but highly expressed in skin and pancreas with other tissues including kidney cortex, endocervix, testis, pituitary, liver, and spleen also showing robust expression.

Domain organisation. Consists of an N-terminal FERM domain linked via a short unstructured region to a large flexible C-terminal rod which contains 13 amphipathic helical bundles (R1-R13). The rod begins with a five-helix bundle (R1) followed by three four-helix bundles (R2-R4). These are followed by a series of eight five-helix bundles (R5-R7 and R9-R13) in which the N- and C-termini are positioned at opposite ends of the bundle, creating a linear chain. The four-helix bundle R8 does not disrupt the chain because it is inserted into a loop in the R7 five-helix bundle. The uneven distribution of four- and five-helix bundles creates two distinctly different zones: a compact N-terminal region sensitive to stretch and a linear C-terminal region that is optimal for force transmission.

Induction. By a combination of TGFB and EGF.

Miscellaneous. Shows reduced mechanical stability compared to isoform 1. Shows altered focal adhesion formation compared to isoform 1 with cells having a greater number of small adhesions compared to those expressing isoform 1. Expression in cancer cells is associated with altered drug responses. Cells show increased sensitivity to EGFR inhibitors but are resistant to drugs targeting PI3K signaling and cytoskeleton regulation.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y490-1	1	yes
Q9Y490-2	2

RefSeq proteins (1): NP_006280* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000299	FERM_domain	Domain
IPR002404	IRS_PTB	Domain
IPR002558	ILWEQ_dom	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR014352	FERM/acyl-CoA-bd_prot_sf	Homologous_superfamily
IPR015009	Vinculin-bd_dom	Domain
IPR015224	Talin_cent	Domain
IPR019747	FERM_CS	Conserved_site
IPR019748	FERM_central	Domain
IPR019749	Band_41_domain	Domain
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR032425	FERM_f0	Domain
IPR035963	FERM_2	Homologous_superfamily
IPR035964	I/LWEQ_dom_sf	Homologous_superfamily
IPR036476	Talin_cent_sf	Homologous_superfamily
IPR036723	Alpha-catenin/vinculin-like_sf	Homologous_superfamily
IPR037438	Talin1/2-RS	Domain
IPR049108	Talin_R4	Domain
IPR054060	TLN1-like_RS	Domain
IPR054082	Talin_IBS2B	Domain
IPR057346	Talin1/2_VBS2	Domain

Pfam: PF01608, PF02174, PF08913, PF09141, PF16511, PF21692, PF21865, PF21896, PF25177

UniProt features (62 total): modified residue 20, region of interest 17, sequence conflict 7, strand 7, sequence variant 3, helix 3, domain 2, chain 1, splice variant 1, turn 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
4DJ9	X-RAY DIFFRACTION	2.25
1SYQ	X-RAY DIFFRACTION	2.42
6R9T	ELECTRON MICROSCOPY	6.2
2MWN	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y490-F1	75.81	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (20): 167, 405, 425, 446, 620, 729, 1021, 1116, 1142, 1201, 1225, 1263, 1323, 1544, 1849, 1855, 1878, 2031, 2040, 2115

Function

Pathways and Gene Ontology

Reactome pathways

15 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation
R-HSA-354192	Integrin signaling
R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins
R-HSA-372708	p130Cas linkage to MAPK signaling for integrins
R-HSA-381038	XBP1(S) activates chaperone genes
R-HSA-399955	SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
R-HSA-445355	Smooth Muscle Contraction
R-HSA-5674135	MAP2K and MAPK activation
R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants
R-HSA-6802948	Signaling by high-kinase activity BRAF mutants
R-HSA-6802952	Signaling by BRAF and RAF1 fusions
R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-9649948	Signaling downstream of RAS mutants
R-HSA-9656223	Signaling by RAF1 mutants
R-HSA-9856530	High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells

MSigDB gene sets: 314 (showing top): BIOCARTA_RHO_PATHWAY, REACTOME_UNFOLDED_PROTEIN_RESPONSE_UPR, GOBP_CYTOPLASMIC_MICROTUBULE_ORGANIZATION, MODULE_255, REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, GOBP_PLATELET_ACTIVATION, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_FOCAL_ADHESION_ASSEMBLY, MODULE_317, GOCC_CELL_SURFACE, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, RACCACAR_AML_Q6, TGACCTY_ERR1_Q2, GOCC_RUFFLE

GO Biological Process (11): cell-cell junction assembly (GO:0007043), cell-substrate junction assembly (GO:0007044), integrin-mediated signaling pathway (GO:0007229), actin cytoskeleton organization (GO:0030036), cortical actin cytoskeleton organization (GO:0030866), integrin activation (GO:0033622), cortical microtubule organization (GO:0043622), regulation of focal adhesion assembly (GO:0051893), platelet aggregation (GO:0070527), cell-cell adhesion (GO:0098609), cell adhesion (GO:0007155)

GO Molecular Function (10): phosphatidylserine binding (GO:0001786), integrin binding (GO:0005178), structural constituent of cytoskeleton (GO:0005200), vinculin binding (GO:0017166), LIM domain binding (GO:0030274), phosphatidylinositol binding (GO:0035091), cadherin binding (GO:0045296), actin filament binding (GO:0051015), actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (14): ruffle (GO:0001726), extracellular region (GO:0005576), cytoplasm (GO:0005737), cytosol (GO:0005829), cytoskeleton (GO:0005856), plasma membrane (GO:0005886), adherens junction (GO:0005912), focal adhesion (GO:0005925), cell surface (GO:0009986), ruffle membrane (GO:0032587), extracellular exosome (GO:0070062), membrane (GO:0016020), cell projection (GO:0042995), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-11 pathways:

Category	Pathways
Oncogenic MAPK signaling	5
Integrin signaling	2
Response to elevated platelet cytosolic Ca2+	1
Signal Transduction	1
Platelet Aggregation (Plug Formation)	1
IRE1alpha activates chaperones	1
Semaphorin interactions	1
Muscle contraction	1
RAF/MAP kinase cascade	1
Signaling by RAS mutants	1
Response of endothelial cells to shear stress	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
cell junction assembly	2
cytoskeleton organization	2
cortical cytoskeleton organization	2
anion binding	2
protein-containing complex binding	2
cell adhesion molecule binding	2
cytoskeletal protein binding	2
cell-cell junction organization	1
cell-substrate junction organization	1
cell surface receptor signaling pathway	1
actin filament-based process	1
actin cytoskeleton organization	1
protein-containing complex assembly	1
cytoplasmic microtubule organization	1
regulation of cell-matrix adhesion	1
focal adhesion assembly	1
regulation of cell-substrate junction assembly	1
platelet activation	1
homotypic cell-cell adhesion	1
cell adhesion	1
cellular process	1
phospholipid binding	1
modified amino acid binding	1
signaling receptor binding	1
structural molecule activity	1
cytoskeleton	1
protein domain specific binding	1
actin binding	1
binding	1
cell leading edge	1
plasma membrane bounded cell projection	1
intracellular anatomical structure	1
cytoplasm	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
cell-cell junction	1
cell-substrate junction	1
ruffle	1

Protein interactions and networks

STRING

2668 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TLN1	VCL	P18206	999
TLN1	PXN	P49023	999
TLN1	ZYX	Q15942	999
TLN1	FLNA	P21333	997
TLN1	PTK2	Q05397	997
TLN1	FLNB	O75369	996
TLN1	SRC	P12931	996
TLN1	BCAR1	P56945	996
TLN1	ILK	P57043	996
TLN1	FLNC	Q14315	996
TLN1	APBB1IP	Q7Z5R6	995
TLN1	ITGB1	P05556	994
TLN1	ITGB3	P05106	991
TLN1	FN1	P02751	988
TLN1	VASP	P50552	980

IntAct

175 interactions, top by confidence:

A	B	Type	Score
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
TLN1	ITGB3	psi-mi:“MI:0407”(direct interaction)	0.720
ITGB3	TLN1	psi-mi:“MI:0407”(direct interaction)	0.720
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
VCP	UBXN8	psi-mi:“MI:0914”(association)	0.690
GTF2H4	GTF2H1	psi-mi:“MI:0914”(association)	0.670
VCAM1	ITGB1	psi-mi:“MI:0914”(association)	0.660
KANK4	TRAPPC3	psi-mi:“MI:0914”(association)	0.640
KANK4	TRAPPC10	psi-mi:“MI:0914”(association)	0.640
RET	TLN1	psi-mi:“MI:0407”(direct interaction)	0.620
TLN1	RET	psi-mi:“MI:0407”(direct interaction)	0.620
TLN1	PIP5K1C	psi-mi:“MI:0407”(direct interaction)	0.610
PIP5K1C	TLN1	psi-mi:“MI:0407”(direct interaction)	0.610
ARHGAP31	TLN1	psi-mi:“MI:0407”(direct interaction)	0.590
	TLN1	psi-mi:“MI:0407”(direct interaction)	0.590
TLN1	ITGB1	psi-mi:“MI:0407”(direct interaction)	0.540
ITGB1	TLN1	psi-mi:“MI:0915”(physical association)	0.540
SNRNP27	UBA6	psi-mi:“MI:0914”(association)	0.530
BLVRA	DDHD2	psi-mi:“MI:0914”(association)	0.530
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530

BioGRID (372): TLN1 (Affinity Capture-RNA), TLN1 (Affinity Capture-RNA), TLN1 (Affinity Capture-RNA), TLN1 (Affinity Capture-MS), TLN1 (Affinity Capture-MS), TLN1 (Affinity Capture-MS), TLN1 (Affinity Capture-MS), TLN1 (Affinity Capture-MS), NMD3 (Co-fractionation), RNASEH2C (Co-fractionation), TLN1 (Co-fractionation), TLN1 (Co-fractionation), TLN1 (Co-fractionation), TLN1 (Affinity Capture-MS), TLN1 (Proximity Label-MS)

ESM2 similar proteins: A0A3B6UES5, A0A3G2LGI8, D3ZHV2, G8JYB2, O46037, O60437, P0CE94, P0CE95, P11533, P12003, P18206, P19826, P26039, P26231, P26234, P30427, P33338, P35220, P35221, P54939, P85972, P90947, Q02328, Q03001, Q04615, Q15149, Q17162, Q3MHM6, Q54K81, Q54MH2, Q59I72, Q64727, Q6ZWR6, Q71LX4, Q8MSU4, Q91ZU6, Q95XZ0, Q9ERE8, Q9H1K6, Q9MBF8

Diamond homologs: A0A3G2LGI8, F1REV3, P0CE94, P26039, P54939, P59113, Q18685, Q54EW0, Q5R8M5, Q71LX4, Q9BQL6, Q9P6L5, Q9Y490, Q9Y4G6, Q9WU22, F1Q8X5, P0CE95, Q32LP0, Q86UX7, Q8CIB5, Q8K1B8, Q96AC1, Q9VZI3, O35763, P0CD60, P26038, P26040, P26041, P26042, P31976, P31977, Q2HJ49, Q54K81, Q6S5J6

SIGNOR signaling

35 interactions.

A	Effect	B	Mechanism
CDK5	up-regulates	TLN1	phosphorylation
TLN1	“up-regulates activity”	“AIIB/b3 integrin”	binding
PTK2	“up-regulates activity”	TLN1	binding
TLN1	“up-regulates activity”	ITGB1	binding
TLN1	“up-regulates activity”	“A1/b1 integrin”	binding
TLN1	“up-regulates activity”	“A2/b1 integrin”	binding
TLN1	“up-regulates activity”	“A3/b1 integrin”	binding
TLN1	“up-regulates activity”	“A4/b1 integrin”	binding
TLN1	“up-regulates activity”	“A5/b1 integrin”	binding
TLN1	“up-regulates activity”	“A6/b1 integrin”	binding
TLN1	“up-regulates activity”	“A8/b1 integrin”	binding
TLN1	“up-regulates activity”	“A9/b1 integrin”	binding
TLN1	“up-regulates activity”	“A10/b1 integrin”	binding
TLN1	“up-regulates activity”	“A11/b1 integrin”	binding
TLN1	“up-regulates activity”	ITGB2	binding
TLN1	“up-regulates activity”	“AL/b2 integrin”	binding
TLN1	“up-regulates activity”	“AM/b2 integrin”	binding
TLN1	“up-regulates activity”	“AX/b2 integrin”	binding
TLN1	“up-regulates activity”	“Av/b2 integrin”	binding
TLN1	“up-regulates activity”	“AD/b2 integrin”	binding
TLN1	“up-regulates activity”	ITGB3	binding
TLN1	“up-regulates activity”	“Av/b3 integrin”	binding
TLN1	“up-regulates activity”	ITGB4	binding
TLN1	“up-regulates activity”	“A6/b4 integrin”	binding
TLN1	“up-regulates activity”	ITGB5	binding
TLN1	“up-regulates activity”	“Av/b5 integrin”	binding
TLN1	“up-regulates activity”	ITGB6	binding
TLN1	“up-regulates activity”	“Av/b6 integrin”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 179 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Dengue Virus Genome Translation and Replication	6	13.6×	2e-03
Dengue Virus-Host Interactions	12	3.9×	1e-02
Infectious disease	19	3.4×	2e-03
Viral Infection Pathways	15	3.3×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

321 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	225
Likely benign	16
Benign	8

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1691453	NM_006289.4(TLN1):c.7188+2T>C	Likely pathogenic

SpliceAI

6988 predictions. Top by Δscore:

Variant	Effect	Δscore
9:35697912:ATGAT:A	acceptor_gain	1.0000
9:35697913:TGAT:T	acceptor_gain	1.0000
9:35697914:GAT:G	acceptor_gain	1.0000
9:35697916:TCTGA:T	acceptor_loss	1.0000
9:35697917:C:CA	acceptor_loss	1.0000
9:35697917:C:CC	acceptor_gain	1.0000
9:35697918:T:C	acceptor_loss	1.0000
9:35697923:G:C	acceptor_gain	1.0000
9:35697923:G:GC	acceptor_gain	1.0000
9:35698038:GCTCA:G	donor_loss	1.0000
9:35698039:CTCA:C	donor_loss	1.0000
9:35698041:CACC:C	donor_loss	1.0000
9:35698042:A:AC	donor_gain	1.0000
9:35698043:C:CC	donor_gain	1.0000
9:35698043:C:CG	donor_loss	1.0000
9:35698168:GCAGC:G	acceptor_gain	1.0000
9:35698169:CAGC:C	acceptor_gain	1.0000
9:35698169:CAGCC:C	acceptor_gain	1.0000
9:35698170:AGC:A	acceptor_gain	1.0000
9:35698171:GC:G	acceptor_gain	1.0000
9:35698172:CC:C	acceptor_gain	1.0000
9:35698173:C:A	acceptor_loss	1.0000
9:35698173:C:CC	acceptor_gain	1.0000
9:35698173:C:T	acceptor_gain	1.0000
9:35698174:T:A	acceptor_loss	1.0000
9:35698178:C:CT	acceptor_gain	1.0000
9:35698179:A:T	acceptor_gain	1.0000
9:35698317:TCTCA:T	donor_loss	1.0000
9:35698318:CTCA:C	donor_loss	1.0000
9:35698319:TCAC:T	donor_loss	1.0000

AlphaMissense

16465 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:35697852:A:G	L2522P	1.000
9:35697861:C:G	R2519P	1.000
9:35697865:C:G	A2518P	1.000
9:35697873:A:G	L2515P	1.000
9:35697891:A:G	L2509P	1.000
9:35697907:C:G	A2504P	1.000
9:35698135:A:G	L2470P	1.000
9:35698148:C:G	A2466P	1.000
9:35698327:A:G	L2456P	1.000
9:35698378:A:G	L2439P	1.000
9:35698381:A:G	L2438P	1.000
9:35698381:A:T	L2438H	1.000
9:35698411:G:T	A2428D	1.000
9:35698412:C:G	A2428P	1.000
9:35698423:A:G	L2424P	1.000
9:35698466:C:G	A2410P	1.000
9:35698474:A:G	L2407P	1.000
9:35698487:C:G	A2403P	1.000
9:35698627:A:G	L2393P	1.000
9:35698638:C:A	W2389C	1.000
9:35698638:C:G	W2389C	1.000
9:35698640:A:G	W2389R	1.000
9:35698640:A:T	W2389R	1.000
9:35698857:A:G	L2359P	1.000
9:35698870:C:G	A2355P	1.000
9:35698888:C:G	A2349P	1.000
9:35699073:C:G	A2320P	1.000
9:35699105:A:G	L2309P	1.000
9:35699382:A:G	L2283P	1.000
9:35700227:G:C	S2208R	1.000

dbSNP variants (sampled 300 via entrez): RS1000049032 (9:35722738 A>G,T), RS1000058902 (9:35712412 G>A), RS1000074681 (9:35719301 A>C), RS1000246790 (9:35709315 CCAAAAAAA>C), RS1000482863 (9:35722448 G>A), RS1000535156 (9:35724308 G>A), RS1000622693 (9:35730746 T>G), RS1000779511 (9:35730392 T>G), RS1000795965 (9:35728674 T>C), RS1000858017 (9:35704229 G>A), RS1000925805 (9:35711152 T>A,C), RS1001025905 (9:35718118 C>T), RS1001055982 (9:35723893 G>A), RS1001077787 (9:35717933 G>A,T), RS1001335963 (9:35697497 G>A,T)

Disease associations

OMIM: gene MIM:186745 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
idiopathic spontaneous coronary artery dissection	Moderate	Autosomal dominant
thrombocytopenia	Limited	Autosomal dominant

Mondo (3): capillary leak syndrome (MONDO:0001956), thrombocytopenia (MONDO:0002049), idiopathic spontaneous coronary artery dissection (MONDO:0007385)

Orphanet (1): Systemic capillary leak syndrome (Orphanet:188)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST002122_3	IgE levels in asthmatics	8.000000e-06
GCST004616_199	Platelet distribution width	3.000000e-10
GCST010703_52	Brain morphology (MOSTest)	1.000000e-08
GCST90002388_219	Lymphocyte count	8.000000e-17
GCST90002393_375	Monocyte count	7.000000e-10
GCST90002400_373	Plateletcrit	7.000000e-14
GCST90002401_479	Platelet distribution width	8.000000e-25

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0007984	platelet component distribution width
EFO:0004346	neuroimaging measurement
EFO:0004587	lymphocyte count
EFO:0005091	monocyte count
EFO:0007985	platelet crit

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D019559	Capillary Leak Syndrome	C14.907.218
D013921	Thrombocytopenia	C15.378.140.855; C15.378.243.937
C565153	Coronary Artery Dissection, Spontaneous (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067124 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2295795	TLN1		0.00	0
rs10814270	TLN1		0.00	0

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.38	Kd	41.84	nM	CHEMBL5653589
7.38	ED50	41.84	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149595: Binding affinity to human TLN1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0418	uM

CTD chemical–gene interactions

57 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression, affects cotreatment	3
Benzo(a)pyrene	decreases methylation, increases expression, affects methylation	3
Cadmium Chloride	increases expression	3
bisphenol F	increases expression, affects cotreatment, decreases expression	2
methylmercuric chloride	increases expression	2
2-(4-(biphenyl-4-sulfonyl)-piperazin-1-yl)-6,7-dipropoxyquinazolin-4-yl-amine	decreases expression, decreases reaction, increases expression	2
Cisplatin	affects response to substance, increases reaction, increases response to substance	2
Aflatoxin B1	decreases methylation	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression, affects localization, increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
pentabromodiphenyl ether	increases expression	1
CGP 52608	affects binding, increases reaction	1
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	increases reaction, increases response to substance	1
ciguatoxin 1B (CTX 1B)	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
benzyloxycarbonyl-valyl-alanyl-aspartic acid	increases reaction, increases response to substance	1
bisphenol S	increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Arsenic Trioxide	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652637	Binding	Binding affinity to human TLN1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7ZY	Abcam Raji TLN1 KO	Cancer cell line	Male
CVCL_C0AS	Abcam THP-1 TLN1 KO	Cancer cell line	Male
CVCL_C7CF	Abcam PC-3 TLN1 KO	Cancer cell line	Male
CVCL_E0ZE	Ubigene NB4 TLN1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

244 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00039858	PHASE4	COMPLETED	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
NCT00239733	PHASE4	TERMINATED	Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
NCT00907478	PHASE4	COMPLETED	Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
NCT01727401	PHASE4	TERMINATED	Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
NCT02032134	PHASE4	TERMINATED	Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
NCT02267993	PHASE4	COMPLETED	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
NCT03633019	PHASE4	UNKNOWN	High-dose Use of rhTPO in CIT Patients
NCT03688191	PHASE4	UNKNOWN	Study of Sirolimus in CTD-TP in China
NCT04906083	PHASE4	UNKNOWN	Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
NCT05217719	PHASE4	UNKNOWN	Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT05382013	PHASE4	UNKNOWN	Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment
NCT05944458	PHASE4	COMPLETED	Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients
NCT06562738	PHASE4	RECRUITING	Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
NCT00037791	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00039910	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00073580	PHASE3	COMPLETED	Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
NCT00102323	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102336	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00116688	PHASE3	COMPLETED	Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00128713	PHASE3	COMPLETED	Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00151866	PHASE3	COMPLETED	Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
NCT00261924	PHASE3	COMPLETED	Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
NCT00415532	PHASE3	COMPLETED	Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00420914	PHASE3	TERMINATED	Strategies for Transfusion of Platelets (SToP)
NCT00501345	PHASE3	TERMINATED	Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00508820	PHASE3	COMPLETED	An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00678587	PHASE3	TERMINATED	Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
NCT01438840	PHASE3	COMPLETED	Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
NCT01444417	PHASE3	COMPLETED	Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01805648	PHASE3	UNKNOWN	Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
NCT02244658	PHASE3	UNKNOWN	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
NCT02389621	PHASE3	COMPLETED	Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
NCT02444728	PHASE3	TERMINATED	Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
NCT02487563	PHASE3	COMPLETED	Prospective Study of Patients With Thrombocytopenia Following HSCT
NCT02578901	PHASE3	COMPLETED	American Trial Using Tranexamic Acid in Thrombocytopenia
NCT03326843	PHASE3	TERMINATED	Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
NCT03515096	PHASE3	COMPLETED	Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
NCT05563064	PHASE3	UNKNOWN	Effect of Herbal Formulation on Thrombocytes Count
NCT07442513	PHASE3	RECRUITING	Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT